| Literature DB >> 30409778 |
.
Abstract
In a phase III trial, first-line treatment with single-agent pembrolizumab led to deep and durable responses among patients with head and neck tumors that expressed high levels of PD-L1. ©2018 American Association for Cancer Research.Entities:
Year: 2018 PMID： 30409778 DOI： 10.1158/2159-8290.CD-NB2018-151
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397